Abstracts tagged "Clinical practice guidelines"

Abstract Number: 582 • 2013 ACR/ARHP Annual Meeting
A Real-World Survey Of Clinical Practice Among Rheumatologists and Nephrologists In The United States Reveals Differences In Care Of Non-Nephritis Systemic Lupus Erythematosus and Lupus Nephritis As Compared With American College Of Rheumatology Treatment Guidelines
Neelufar Mozaffarian¹, Steve Lobosco² and Adam Roughley², ¹AbbVie, North Chicago, IL, ²Adelphi Real World Ltd., Macclesfield, United Kingdom
Background/Purpose: Current pharmacotherapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN) includes combinations of nonsteroidal anti–inflammatory drugs (NSAIDs), antimalarials (AMs), glucocorticoids (GCs), and cytotoxic…
Abstract Number: 1845 • 2012 ACR/ARHP Annual Meeting
Inequalities Across 46 European Countries in Clinical Eligibility Criteria for the Start of A First (Reimbursed) Biologic in Patients with Rheumatoid Arthritis
Polina Putrik¹, Sofia Ramiro², Tore K. Kvien³, Tuulikki Sokka⁴, Till Uhlig³, Annelies Boonen⁵ and Equity in Clinical Eligibility Criteria for RA treatment⁶, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁶European Region
Background/Purpose: In the treatment of patients with RA, strategies that include biologics have resulted in a better outcome for patients with regard to disease activity,…
Abstract Number: 1573 • 2012 ACR/ARHP Annual Meeting
Baseline Screening Recommendations for Rheumatoid Arthritis Patients Treated with Disease Modifying Anti-Rheumatic Drugs: Does an Educational Intervention Change Practice in an Outpatient Clinic?
Debra C. Lloyd¹, John N. Mecchella² and Daniel Albert³, ¹Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, ²Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, ³Rheumatology, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Lebanon, NH
Background/Purpose: In 2008, the American College of Rheumatology (ACR) developed recommendations for use of non-biologic and biologic DMARDs in the treatment of rheumatoid arthritis (RA). …
Abstract Number: 768 • 2012 ACR/ARHP Annual Meeting
An Easy to Use Referral Model for Arthritis From the Rotterdam Early Arthitis Cohort
C. Alves¹, Jolanda J. Luime¹, Darian P. Shackleton², P.J. Barendregt³, A.H. Gerards⁴ and Johanna M.W. Hazes¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Medisch Centrum Parklaan, Netherlands, ³Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands
Background/Purpose: The first hurdle general practitioners (GPs) face to identify Rheumatoid Arthritis(RA) is to recognize presence of arthritis. Due to the low incidence of arthritis…
Abstract Number: 96 • 2012 ACR/ARHP Annual Meeting
Quality of Care: Reference and Counter Reference From Family Physicians and Rheumatologists’ perspectives– A Pilot Study
Thiago D. Baumgratz¹, Raphael Battisti¹, Mirella Cuziol², Ana Carolina Reiff Janini², R.A. Levy³ and Mirhelen M. Abreu⁴, ¹Medical Student at Universidade Federal de São Carlos, São Carlos, Brazil, ²Medicine, Medical Student at Universidade Federal de São Carlos, São Carlos, Brazil, ³Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil, ⁴Universidade Federal de São Carlos, São Carlos SP, Brazil
Background/Purpose: We delineated family physicians' and rheumatologists’ point of view when primary care is facing cases of rheumatic diseases. We also tried to identify barriers…
Abstract Number: 75 • 2012 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Associated with Achieving and Maintaining Low Disease Activity in Rheumatoid Arthritis
Martin J. Bergman¹, James W. Shaw², Mary Cifaldi³, Gourab De⁴, Tony He⁵, Rajeev Ayyagari⁵ and James Signorovitch⁵, ¹Taylor Hospital, Ridley Park, PA, ²Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL, ³Abbott Laboratories, Abbott Park, IL, ⁴Analysis Group, Inc., New York, NY, ⁵Analysis Group, Inc., Boston, MA
Background/Purpose: Treat-to-target (T2T) guidelines for rheumatoid arthritis (RA) recognize low disease activity (LDA) as an acceptable therapeutic goal, particularly in patients with longstanding disease. The…
Abstract Number: 84 • 2012 ACR/ARHP Annual Meeting
Benefits of Treat-to-Target Guideline Compliance in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis
Martin J. Bergman¹, James W. Shaw², Mary A. Cifaldi³, Annie Guerin⁴, Pooja Chopra⁵ and James Signorovitch⁵, ¹Taylor Hospital, Ridley Park, PA, ²Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL, ³Abbott Laboratories, Abbott Park, IL, ⁴Analysis Group, Inc., Montreal, QC, Canada, ⁵Analysis Group, Inc., Boston, MA
Background/Purpose: To achieve clinical remission/low disease activity in patients with rheumatoid arthritis (RA), the treat-to-target (T2T) guidelines recommend frequent disease monitoring through patient-rheumatologist interactions. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].